Tagged with Partnership

Pharma Thilo Stadler speaks passionately about Grünenthal’s collaborative partnerships, company goals, and workforce engagement; revealing himself to be someone who truly believes in Grünenthal’s business. You currently hold the position of Regional General Manager South Europe and the Nordics and Managing Director of the Italian subsidiary. What were the main objectives…

Pharma Lyonbiopole was established in 2005 as a cluster designed to support the local business community focused on infectious diseases and microbiology. Philippe Archinard, the Biopole’s president, traces the evolution of the cluster over the last decade while underscoring the critical importance of transparency and collaboration between government, industry and academia.…

Pharma Charles-Henri Bodin, General Manager of Pierre Fabre, explains how the recent agreement with Pfizer on Toviaz will enlarge their footprint in Italy and how partnerships will play an increasing role in future growth. You’ve been with PF since 1999, serving in various positions in France and Italy before becoming GM…

Pharma Raffaele Stefanelli discusses the challenges of the medtech industry in Italy, the contribution of the Italian research community to Boston Scientific globally, and innovative partnership models. Could you introduce yourself to our readers as you currently hold two positions within Boston Scientific: managing director of the affiliate as well as…

Pharma The Dedicated Chair of the Pharmaceutical Committee of the Association of Health Insurance Companies speaks about drug pricing procedures, the partnership with the pharmaceutical industry, as well as her overarching vision for the organization. The Association of Health Insurance Companies of the Czech Republic (CR CAP) was established in 1997…

Pharma Luigi Boggio, President of Assobiomedica, the association representing the medtech industry, and MD of B. Braun Italy, calls on the Italian government to implement a national system that measures the impact of medtech innovations. What are the exact activities of Assobiomedica and what are your main priorities as President? The…

Pharma The AIFP’s Jakub Dvořáček explains the recently launched tool for information disclosure between pharmaceutical companies and doctors, highlighting the significance it holds for industry and country. Furthermore, he reviews the Czech Republic’s attractiveness as a location for pharma companies. When we met you in 2012, you named re-exporting and a…

Pharma Simona Falciai, General Manager of Shionogi, provides insights into the launch of the Italian affiliate, how the company is catering to a key unmet medical need with Ospemifene, the first oral, non-estrogenic drug in the field of vulvar and vaginal atrophy, and the central role of partnerships in the company’s…

Pharma Thierry Guillot, president of Chugai Pharma France, talks about the challenge of transitioning from a small organization, which revolved around one main product into a larger entity capable of delivering multiple products and solutions; he also reveals how since 2008, Chugai and Roche have worked together on marketing and business…

Pharma In keeping with its reputation as a forerunner, the Dutch healthcare eco-system is currently reinventing itself to ensure it remains ahead of the game in terms of both innovation and excellence. Market and patient access, transparency, cost-effectiveness and process innovation all feature prominently as industry and government alike band together…

Pharma The President and MD of Abiogen Pharma discusses his family company’s recent milestones, the reasons for persisting with local manufacturing, and the benefits of international partnerships. You created Abiogen back in 1997, following the acquisition of Istituto Gentili by MSD, in order to maintain your family’s entrepreneurial tradition and build…

Pharma Stéphane Thiroloix, CEO of the independent and family owned Mayoly Spindler, reveals how their vision is to become a reference company internationally in the field of gastroenterology and dermocosmetics; how already forty-five percent of their business is done overseas; and how on current projections, excluding external growth, they anticipate to…